good to see increased relenza production

"This was recently demonstrated by a packaging launch involving GlaxoSmithKline’s anti-viral product Relenza®, which has been recommended by a number of global health authorities for treatment of H1N1 influenza. The Corby team moved from preliminary discussion through design, implementation, validation, and into full production in just twelve weeks, helping GlaxoSmithKline meet increasing demand for the product.
"

http://www.businesswire.com/portal/site/google/?ndmViewId=news_view&newsId=20091006005374&newsLang=en